GROSSPATTERN / FUNDAMENTAL STATE / POINT IN TIME

LAB · Jun 30, 2025

STANDARD BIOTOOLS INC.. A multidimensional configuration derived from the filing available at this observation—never a composite score or recommendation.

STATE CAPABILITYLEVEL 3[email protected]

Inspectable configuration

State dimensions

Filing0000950170-25-109388General Corporate

Capex intensityRAWCurrent state valid · history insufficient

Evidence method

Level · gp.fundamentals.capex_revenue_ratio

8.67% · OPTIONAL · NOT_ENOUGH_HISTORY

Operating cash generationRAWCurrent state valid · history insufficient

Evidence method

Ratio · gp.fundamentals.operating_cash_flow + gp.fundamentals.revenue

-94.97% · OPTIONAL · NOT_ENOUGH_HISTORY

Revenue growthRAWCurrent state valid · history insufficient

Evidence method

Yoy · gp.fundamentals.revenue

-41.51% · CORE · NOT_ENOUGH_HISTORY

Inventory pressureRAWCurrent state valid · history insufficient

Evidence method

Level · gp.fundamentals.inventory_revenue_ratio

111.07% · OPTIONAL · NOT_ENOUGH_HISTORY

Gross marginRAWCurrent state valid · history insufficient

Evidence method

Level · gp.fundamentals.gross_margin

48.84% · CORE · NOT_ENOUGH_HISTORY

Operating marginRAWCurrent state valid · history insufficient

Evidence method

Level · gp.fundamentals.operating_margin

-118.08% · CORE · NOT_ENOUGH_HISTORY

R&D intensityRAWCurrent state valid · history insufficient

Evidence method

Ratio · gp.fundamentals.rnd + gp.fundamentals.revenue

28.59% · OPTIONAL · NOT_ENOUGH_HISTORY

SBC intensityRAWCurrent state valid · history insufficient

Evidence method

Level · gp.fundamentals.sbc_revenue_ratio

24.69% · OPTIONAL · NOT_ENOUGH_HISTORY

As-filed lineage

Fundamental state history

Each observation is tied to the filing and facts available at that report date. Amendments remain separate.

History9 statesHistory building

Jun 30, 20240/6 normalizedLevel 3 Sep 30, 20240/8 normalizedLevel 3 Dec 31, 20240/8 normalizedLevel 3 Mar 31, 20250/7 normalizedLevel 3 Jun 30, 20250/8 normalizedLevel 3 Sep 30, 20250/8 normalizedLevel 3 Dec 31, 20250/8 normalizedLevel 3 Mar 31, 20260/8 normalizedLevel 3 Jun 30, 20265/8 normalizedLevel 3

Period transition

What moved in the state?

Capex Intensity Decreased

Previous: 12.39%
Current: 8.67%
Delta: -3.72%

Cash Generation Decreased

Previous: -74.23%
Current: -94.97%
Delta: -20.74%

Inventory Pressure Increased

Previous: 103.26%
Current: 111.07%
Delta: 7.80%

Margin Increased

Previous: 48.39%
Current: 48.84%
Delta: 0.45%

Profitability Decreased

Previous: -80.82%
Current: -118.08%
Delta: -37.26%

R And D Intensity Increased

Previous: 27.77%
Current: 28.59%
Delta: 0.82%

Sbc Intensity Increased

Previous: 22.08%
Current: 24.69%
Delta: 2.60%

Self-history only

Previous similar states

Similarity compares compatible valid dimensions from this issuer's own point-in-time history. No market-return claim is attached.

Not enough compatible prior states for a transparent self-history match.

Research Graph

Related governed research

Transitioned To · LAB Fundamental State →Has State · STANDARD BIOTOOLS INC. →Transitioned To · LAB Fundamental State →Transitioned To · LAB CAPEX_INTENSITY_DECREASED →Transitioned To · LAB CASH_GENERATION_DECREASED →Transitioned To · LAB INVENTORY_PRESSURE_INCREASED →Transitioned To · LAB MARGIN_INCREASED →Transitioned To · LAB PROFITABILITY_DECREASED →Transitioned To · LAB R_AND_D_INTENSITY_INCREASED →Transitioned To · LAB SBC_INTENSITY_INCREASED →

Method Percentiles and historical matches use only observations available at each point in time. Missing dimensions remain missing. Public price outcomes and cross-market analogues are deliberately absent.